|1.||Growcott, Jim: 2 articles (07/2009 - 09/2007)|
|2.||Forder, Cheryl: 2 articles (07/2009 - 09/2007)|
|3.||Bhattacharya, Sujoy: 1 article (03/2014)|
|4.||Ray, Ramesh M: 1 article (03/2014)|
|5.||Johnson, Leonard R: 1 article (03/2014)|
|6.||Raghavan, Pavithra: 1 article (11/2012)|
|7.||Tomimatsu, Nozomi: 1 article (11/2012)|
|8.||Chan, Norman: 1 article (11/2012)|
|9.||Bristow, Robert G: 1 article (11/2012)|
|10.||Tumati, Vasu: 1 article (11/2012)|
11/15/2012 - "This study supports the evaluation of newer generation Cdk inhibitors, such as AZD5438, as potent radiosensitizers in NSCLC models, especially in tumors that demonstrate variable intrinsic radiation responses."
11/15/2012 - "Combined treatment with AZD5438 and irradiation also enhanced tumor growth delay, with an enhancement factor ranging from 1.2-1.7. "
09/01/2007 - "The modest PD effect, short plasma t1/2 and close PK-PD relationship suggest that multiple daily dosing or sustained release formulations at higher doses will be necessary for AZD5438 to achieve sustained inhibition of CDK in human cancers."
07/01/2009 - "In vivo, when orally administered at either 50 mg/kg twice daily or 75 mg/kg once daily, AZD5438 inhibited human tumor xenograft growth (maximum percentage tumor growth inhibition, range, 38-153; P < 0.05). "
07/01/2009 - "Further pharmacodynamic analysis of AZD5438-treated SW620 xenografts showed that efficacious doses of AZD5438 (>40% tumor growth inhibition) maintained suppression of biomarkers, such as phospho-pRbSer(249)/Thr(252), for up to 16 hours following a single oral dose. "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|1.||Cyclin-Dependent Kinases (cdk Proteins)
|2.||Biological Markers (Surrogate Marker)
|3.||4- (6- cyclohexylmethoxy- 9H- purin- 2- ylamino)- N,N- diethylbenzamide
|1.||Heterologous Transplantation (Xenotransplantation)